[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK0786986T3 - Anvendelse af en umættet fedtalkohol - Google Patents

Anvendelse af en umættet fedtalkohol

Info

Publication number
DK0786986T3
DK0786986T3 DK95936554T DK95936554T DK0786986T3 DK 0786986 T3 DK0786986 T3 DK 0786986T3 DK 95936554 T DK95936554 T DK 95936554T DK 95936554 T DK95936554 T DK 95936554T DK 0786986 T3 DK0786986 T3 DK 0786986T3
Authority
DK
Denmark
Prior art keywords
unsaturated fatty
fatty alcohol
provides
macrolide
class
Prior art date
Application number
DK95936554T
Other languages
English (en)
Inventor
Martin Jackman
Xue-Ping Popp
Friedrich Richter
Fritz Schmook
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9421612A external-priority patent/GB9421612D0/en
Priority claimed from GB9422306A external-priority patent/GB9422306D0/en
Priority claimed from GBGB9503553.1A external-priority patent/GB9503553D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK0786986T3 publication Critical patent/DK0786986T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK95936554T 1994-10-26 1995-10-26 Anvendelse af en umættet fedtalkohol DK0786986T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9421612A GB9421612D0 (en) 1994-10-26 1994-10-26 Organic compounds
GB9422306A GB9422306D0 (en) 1994-11-04 1994-11-04 Organic compounds
GBGB9503553.1A GB9503553D0 (en) 1995-02-22 1995-02-22 Organic compounds
PCT/EP1995/004208 WO1996013249A1 (en) 1994-10-26 1995-10-26 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
DK0786986T3 true DK0786986T3 (da) 2002-04-29

Family

ID=27267447

Family Applications (2)

Application Number Title Priority Date Filing Date
DK95936554T DK0786986T3 (da) 1994-10-26 1995-10-26 Anvendelse af en umættet fedtalkohol
DK01117396T DK1147766T3 (da) 1994-10-26 1995-10-26 Farmaceutiske sammensætninger

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK01117396T DK1147766T3 (da) 1994-10-26 1995-10-26 Farmaceutiske sammensætninger

Country Status (26)

Country Link
US (1) US6352998B2 (da)
EP (2) EP0786986B1 (da)
JP (3) JP4155593B2 (da)
KR (1) KR100434682B1 (da)
CN (2) CN1089233C (da)
AT (2) ATE214593T1 (da)
AU (1) AU714254B2 (da)
BR (1) BR9509530A (da)
CA (1) CA2200966C (da)
CY (1) CY2211B1 (da)
CZ (1) CZ289773B6 (da)
DE (3) DE69525957T2 (da)
DK (2) DK0786986T3 (da)
ES (2) ES2173978T3 (da)
FI (2) FI119754B (da)
GB (1) GB2308546B (da)
HK (1) HK1053611A1 (da)
HU (1) HU223840B1 (da)
MX (1) MX9702699A (da)
NO (2) NO316963B1 (da)
NZ (2) NZ331824A (da)
PL (1) PL184750B1 (da)
PT (2) PT1147766E (da)
SI (1) SI0786986T1 (da)
SK (1) SK284591B6 (da)
WO (1) WO1996013249A1 (da)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR004480A1 (es) * 1995-04-06 1998-12-16 Amico Derin C D Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
GB9601120D0 (en) * 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
CZ283516B6 (cs) 1996-09-12 1998-04-15 Galena A.S. Léčivé přípravky, zejména pro vnitřní aplikaci, ve formě samomikroemulgujících terapeutických systémů
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
TW450810B (en) * 1997-02-20 2001-08-21 Fujisawa Pharmaceutical Co Macrolides antibiotic pharmaceutical composition for preventing and treating skin diseases
DE19744621A1 (de) * 1997-10-09 1999-04-15 Muehlbauer Ernst Kg Mischung zur Verwendung als Wundverband
GB9723669D0 (en) * 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
DE19802205A1 (de) * 1998-01-22 1999-07-29 Beiersdorf Ag Kosmetische und dermatologische Zubereitungen, enthaltend erhöhte Elektrolytkonzentrationen
ID25908A (id) * 1998-03-06 2000-11-09 Novartis Ag Prakonsentrat-prakonsentrat emulsi yang mengandung siklosporin atau makrolida
KR100406823B1 (ko) 1998-04-27 2003-11-21 후지사와 야꾸힝 고교 가부시키가이샤 의약 조성물
GB9814640D0 (en) * 1998-07-06 1998-09-02 Fujisawa Pharmaceutical Co New use
GB9826656D0 (en) * 1998-12-03 1999-01-27 Novartis Ag Organic compounds
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
GB0003932D0 (en) * 2000-02-18 2000-04-12 Novartis Ag Pharmaceutical compositions
BR0207321A (pt) * 2001-02-16 2004-02-10 Jomed Gmbh Implantes com fk506
GB0108498D0 (en) * 2001-04-04 2001-05-23 Novartis Ag Organic Compounds
AR035293A1 (es) * 2001-08-23 2004-05-05 Novartis Ag Composicion oftalmica.
AR038628A1 (es) * 2002-03-04 2005-01-19 Novartis Ag Composicion oftalmica
GB0218996D0 (en) * 2002-08-14 2002-09-25 Novartis Ag Organic compounds
EP1594484A2 (en) * 2003-02-17 2005-11-16 Cipla Ltd. Pharmaceutical patch
GB0307869D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
GB0307867D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
GB0307866D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
AU2004258745A1 (en) * 2003-07-31 2005-02-03 Pharmacia & Upjohn Company Llc Dispersible formulation of an anti-inflammatory agent
GB0408070D0 (en) * 2004-04-08 2004-05-12 Novartis Ag Pharmaceutical formulations
CA2556993C (en) * 2004-04-08 2013-05-21 Novartis Ag Pimecrolimus foam composition containing hexylene glycol, optionally oleyl alcohol, dimethylisosorbide and/or medium chain triglycerides
GB0508827D0 (en) * 2005-04-29 2005-06-08 Novartis Ag Cosmeceutical composition
US9205080B2 (en) 2006-11-16 2015-12-08 Transderm, Inc. Methods of treating keratin hyperproliferation disorders using mTOR inhibitors
EP2016935A1 (en) * 2007-07-09 2009-01-21 Intendis GmbH Pharmaceutical composition for topical application of poorly soluble compounds
CN101288643B (zh) * 2008-06-17 2012-11-14 杨喜鸿 含有他克莫司的凝胶剂组合物及其制备方法和药物应用
EP2308468A1 (en) * 2009-10-08 2011-04-13 Novaliq GmbH Novel pharmaceutical composition comprising a macrolide immunosuppressant drug
GB0917816D0 (en) 2009-10-12 2009-11-25 Biotica Tech Ltd Novel compounds and methods for their production
GB0917817D0 (en) 2009-10-12 2009-11-25 Biotica Tech Ltd Novel compounds and methods for their production
EP2366378A1 (en) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulations
JP5674786B2 (ja) * 2010-07-23 2015-02-25 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
WO2012011192A1 (ja) * 2010-07-23 2012-01-26 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
CN102552253A (zh) * 2012-01-17 2012-07-11 唯美度科技（北京）有限公司 一种祛痘用皮肤外用剂
WO2013111817A1 (ja) * 2012-01-25 2013-08-01 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
CA2899206C (en) * 2013-01-24 2019-07-09 Transderm, Inc. Compositions for transdermal delivery of mtor inhibitors
MX367121B (es) * 2013-08-02 2019-08-06 Laboratorio Raam De Sahuayo S A De C V Composición sólida estable de inmunosupresores.
DE102013222164A1 (de) * 2013-10-31 2015-04-30 Deb Ip Limited Stabilisierte multiple Emulsionen als Hautschutzprodukt
US10765665B2 (en) * 2015-11-24 2020-09-08 Melin Jeffrey Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases
CN105663027B (zh) * 2016-04-01 2018-12-18 中国人民解放军广州军区武汉总医院 西罗莫司外用制剂、其制备方法及用途
AU2017247963B2 (en) * 2016-04-04 2022-10-20 Drug Delivery Solutions Limited Topical composition comprising tacrolimus
EP3565520A4 (en) 2017-01-06 2020-08-19 Palvella Therapeutics, Inc. Anhydrous compositions of MTOR inhibitors and method of use
KR101973065B1 (ko) 2017-09-13 2019-04-26 (주)썬테크 풍력 발전기 및 풍력 발전기의 블레이드 팁
EP3542788A1 (en) 2018-03-19 2019-09-25 MC2 Therapeutics Limited Topical composition comprising calcipotriol and betamethasone dipropionate
KR101995905B1 (ko) 2018-03-27 2019-07-04 (주)썬테크 풍력 발전기 및 풍력 발전기의 발전모터
WO2019233722A1 (en) * 2018-06-08 2019-12-12 Almirall, S.A. Pharmaceutical composition comprising tacrolimus
JP2021530463A (ja) 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物および使用方法
WO2024213629A1 (en) * 2023-04-11 2024-10-17 Bausch Health Ireland Limited Topical compositions

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4299826A (en) 1979-10-12 1981-11-10 The Procter & Gamble Company Anti-acne composition
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
GB2212061B (en) 1987-11-09 1991-08-28 Sandoz Ltd Topical compositions comprising 11,28-dioxa-4-azatricyclo [22.3.1.0(4,9)] octacos-18-ene derivatives
JP2799208B2 (ja) 1987-12-09 1998-09-17 フアイソンズ・ピーエルシー マクロ環状化合物
KR0159766B1 (ko) * 1989-10-16 1998-12-01 후지사와 토모키치로 양모제 조성물
ATE126803T1 (de) * 1989-11-09 1995-09-15 Sandoz Ag Heteroatome enthaltende tricyclische verbindungen.
US5061700A (en) 1989-11-16 1991-10-29 Gordon Jay Dow Glyceryl acetate ointment vehicles
WO1991013899A1 (en) 1990-03-12 1991-09-19 Fujisawa Pharmaceutical Co., Ltd. Tricyclo compounds
EP0533930A1 (en) 1990-06-11 1993-03-31 Fujisawa Pharmaceutical Co., Ltd. Use of a macrolide compound such as fk 506 for manufacturing a medicament for treating idiopathic thrombocytopenic purpura and basedow's disease
MY110418A (en) 1990-07-02 1998-05-30 Novartis Ag Heteroatoms-containing tricyclic compounds.
DK0474126T3 (da) * 1990-09-04 1997-04-07 Fujisawa Pharmaceutical Co
US5143918A (en) * 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
PH31204A (en) * 1990-11-02 1998-05-05 Fujisawa Pharmaceutical Co Pharmaceutical composition.
CA2054983A1 (en) * 1990-11-08 1992-05-09 Sotoo Asakura Suspendible composition and process for preparing the same
US5247076A (en) 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
US5252732A (en) 1991-09-09 1993-10-12 Merck & Co., Inc. D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity
US5208241A (en) 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
HUT66531A (en) 1992-05-07 1994-12-28 Sandoz Ag Heteroatoms-containing tricyclic compounds, pharmaceutical prepns contg. them and process for producing them
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
JPH06183970A (ja) * 1992-12-16 1994-07-05 Fujisawa Pharmaceut Co Ltd 医薬用組成物
MY110603A (en) 1993-05-27 1998-08-29 Novartis Ag Tetrahydropyran derivatives
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
EP0724452B1 (de) 1993-10-22 2000-05-24 Hexal Ag Pharmazeutische zusammensetzung mit cyclosporin a, einen vitamin e derivat und einen emulgator

Also Published As

Publication number Publication date
NZ295170A (en) 1999-02-25
HUT77140A (hu) 1998-03-02
NO971951L (no) 1997-04-25
FI119755B (fi) 2009-03-13
FI119754B (fi) 2009-03-13
BR9509530A (pt) 1997-10-14
CY2211B1 (en) 2002-11-08
CZ123297A3 (en) 1997-08-13
KR100434682B1 (ko) 2004-08-18
WO1996013249A1 (en) 1996-05-09
FI20071025A (fi) 2007-12-28
CA2200966C (en) 2006-12-19
DE69525957D1 (de) 2002-04-25
GB2308546A (en) 1997-07-02
SK52097A3 (en) 1997-09-10
FI971018A (fi) 1997-04-18
EP1147766A2 (en) 2001-10-24
DE69534306T2 (de) 2006-04-27
EP0786986B1 (en) 2002-03-20
NO316963B1 (no) 2004-07-12
JP2012131827A (ja) 2012-07-12
CN1089233C (zh) 2002-08-21
NO2004005I2 (no) 2007-06-11
GB2308546B (en) 1999-06-02
SK284591B6 (sk) 2005-07-01
US20010031769A1 (en) 2001-10-18
HU223840B1 (hu) 2005-02-28
EP1147766A3 (en) 2001-10-31
ES2243369T3 (es) 2005-12-01
KR970706796A (ko) 1997-12-01
ATE299017T1 (de) 2005-07-15
FI971018A0 (fi) 1997-03-11
JP4155593B2 (ja) 2008-09-24
NO971951D0 (no) 1997-04-25
ATE214593T1 (de) 2002-04-15
GB9707484D0 (en) 1997-05-28
PL319599A1 (en) 1997-08-18
JP5599422B2 (ja) 2014-10-01
CA2200966A1 (en) 1996-05-09
MX9702699A (es) 1997-06-28
US6352998B2 (en) 2002-03-05
CN1401325A (zh) 2003-03-12
CN1162259A (zh) 1997-10-15
DE69534306D1 (de) 2005-08-11
NO2004005I1 (no) 2004-09-20
NZ331824A (en) 2000-01-28
PL184750B1 (pl) 2002-12-31
AU714254B2 (en) 1999-12-23
JPH10508588A (ja) 1998-08-25
JP2007145860A (ja) 2007-06-14
DE69525957T2 (de) 2002-11-14
DE19581804T1 (de) 1998-01-22
HK1053611A1 (en) 2003-10-31
PT786986E (pt) 2002-07-31
ES2173978T3 (es) 2002-11-01
SI0786986T1 (en) 2002-06-30
EP1147766B1 (en) 2005-07-06
CZ289773B6 (cs) 2002-04-17
DK1147766T3 (da) 2005-08-29
PT1147766E (pt) 2005-11-30
EP0786986A1 (en) 1997-08-06
AU3845195A (en) 1996-05-23
CN100335063C (zh) 2007-09-05

Similar Documents

Publication Publication Date Title
DK0786986T3 (da) Anvendelse af en umættet fedtalkohol
AU1076792A (en) Cosmetic composition
ES2074734T5 (es) Utilizacion de composiciones a base de alcoholes grasos, para la preparacion de emulsiones; procedimiento de preparacion de emulsiones y emulsiones asi obtenidas.
ES2162951T3 (es) Estabilizacion de composiciones de prostaglandina.
ES2177652T3 (es) Nuevas formas de preparacion de ciclosporina para la aplicacion oral con composicion simple y alta biodisponibilidad, y procedimiento para su obtencion.
EP1072246A3 (de) Kosmetische und dermatologische Zubereitungen auf der Grundlage von O/W-Emulsionen
DE69300054D1 (de) Stabile Azelastinhydrochlorid-Zubereitung.
FI972054A (fi) Immunogeenisiä koostumuksia
WO1995023586A3 (de) Kosmetische und/oder pharmazeutische zubereitungen
ATE160938T1 (de) Feste orale pharmazeutische zubereitung mit gemfibrozil als aktiver inhaltsstoff und verfahren zur herstellung
GB9421612D0 (en) Organic compounds
ATE285745T1 (de) Lippenstifte, deren ölanteile nicht ausschwitzen
GB2327610B (en) Macrolide compositions
RU97108135A (ru) Фармацевтические составы
UA26267C2 (uk) Фармацевтичhа мазь, яка hе виявляє подразhювальhої дії hа шкіру